Notable Labs

Notable Labs Diluted EPS

The Diluted Earnings per Share of Notable Labs (NTBLQ) as of Nov 17, 2026 is -3.41 USD. In the previous year, Diluted Earnings per Share was -14.54 USD — a change of -76.54% (higher).

Diluted EPS

-3.41USD

YoY

-76.54%

Last updated:

Diluted Earnings per Share of Notable Labs is 2023 -3.41 USD. Diluted Earnings per Share of Notable Labs was 2022 -14.54 USD. It decreases by -76.54% higher compared to the previous year.

The Notable Labs Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2016
-22.53 USD
Jan 1, 2017
-13.00 USD
Jan 1, 2018
-21.80 USD
Jan 1, 2019
-18.83 USD
Jan 1, 2020
-19.38 USD
Jan 1, 2021
-15.74 USD
Jan 1, 2022
-14.54 USD
Jan 1, 2023
-3.41 USD
The Notable Labs Diluted EPS history
YEARDiluted EPSYoY
-3.41USD-76.54%
-14.54USD-7.62%
-15.74USD-18.78%
-19.38USD+2.92%
-18.83USD-13.62%
-21.80USD+67.69%
-13.00USD-42.30%
-22.53USD-12.20%
-25.66USD-21.86%
-32.84USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Diluted Earnings per Share of Notable Labs is -3.41 USD in 2023.

Diluted Earnings per Share of Notable Labs changed from -14.54 USD to -3.41 USD, representing a -76.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Notable Labs

All Key Metrics — Notable Labs